Chinese IPO

Shanghai Pharma braves weak market with $2.2 billion IPO

Shanghai Pharma's IPO beats the odds to find good demand in difficult market conditions.
<div style="text-align: left;">
China's healthcare market has doubled during the past five years</div>
<div style="text-align: left;"> China's healthcare market has doubled during the past five years</div>

Shanghai Pharmaceuticals Holding kicked off bookbuilding for a $2.2 billion (HK$17.27 billion) initial public offering in Hong Kong yesterday, despite a lukewarm primary market.

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media